129 results about "Immunodiagnostics" patented technology

The present invention is directed to novel and improved methods for humanizing rabbit heavy and light variable regions. The resulting humanized rabbit heavy and light chains and antibodies and antibody fragments containing are well suited for use in immunotherapy and immunodiagnosis as they retain the antigen binding affinity of the parent antibody and based on their very high level of sequence identity to human antibody sequences should be essentially non-immunogenic in humans. The invention exemplifies the protocol for the manufacture of therapeutic humanized anti-human TNF-alpha and anti-human IL-6 antibodies.

Sequences encoding two immunoreactive glycoproteins were cloned from Ehrlichia canis (p153 gene) and Ehrlichia chaffeensis (p156 gene). These two glycoproteins are species-specific immunoreactive orthologs that are useful as subunit vaccines and for serologic and molecular diagnostics for E. canis and E. chaffeensis.

The present disclosure relates to polypeptides, including fusions thereof, nucleic acids, vectors, host cells, immunodiagnostic reagents, kits, and immunoassays for use detecting the presence of HCV antibodies. More specifically, the present invention describes specific NS3 antigens that can be used for the detection of anti-HCV antibodies.

Novel methods, membrane supports and immunodiagnostic test kits for diagnosing Helicobacter pylori infection, are disclosed. The methods can also be used to monitor the progress of treatment of an infection. The methods, supports and kits employ both type-common and type-specific H. pylori antigens and can conveniently be performed in a single-step assay format. The methods provide for highly accurate results and discriminate between H. pylori Type I and H. pylori Type II infection so that an accurate diagnosis can be accomplished.

The invention relates to an SARS-CoV-2 neutralizing antibody detection kit. The SARS-CoV-2 neutralizing antibody detection kit comprises a solid phase carrier, a first antigen and a second antigen ofS protein of SARS-CoV-2, and the second antigen is marked with a signal substance. Whether a tested person is infected by the new coronavirus or not and whether infection risks exist or not are judgedby detecting a neutralizing antibody through an immunodiagnosis technology, and the method is reliable in theory, practical and feasible and can be completed only in a secondary biosafety laboratory.

This invention relates to antibody engineering technology. More particularly, the present invention relates to human IgM antibodies and derivatives thereof, which have novel binding specificity with regard to several oligosaccharide sequences and/or xenoantigenic sialic acid residue. The present invention also relates to processes for making and engineering such novel saccharide and/or NeuGc-binding monoclonal antibodies and to methods for using these antibodies and derivatives thereof in the field of immunodiagnostics, enabling qualitative and quantitative determination of xenoantigenic NeuGc in biological and raw material samples, as well as in immunotherapy, enabling blocking of xenoantigenic NeuGc in patients.

The present invention discloses a quantitative detection kit of free thyroxine (fT4) and a method for detecting the free thyroxine with the detection kit. The detection kit comprises a free thyroxine standard, a free thyroxine antigen marked by horseradish peroxidase, an antibody, a magnetic bead separating agent, luminescence substrate reagent and wash liquid. The method for detecting free thyroxine comprises the following steps: adding the free thyroxine standard and sample to be measured into the test tube, adding the free thyroxine antigen marked by horseradish peroxidase and antibody, after mixing to uniform, incubating for one hour in 37 DEG C, then adding magnetic bead separating agent for stewing for 5 minutes, separating for obtaining the immune magnetic microspheres, discarding the supernate, washing the deposit for two times; adding the luminescence substrate reagent, measuring and analyzing the concentration of free thyroxine in sample to be measured. The quantitative detection kit of free thyroxine and the detection method provided by the invention have the advantages of higher stability, higher sensitivity and higher accuracy, and belong to the technical field of immunodiagnosis.

The invention belongs to the field of bioengineering and provides an Echinococcus granulosusglutathione transferase gene a base sequence of which is shown in SEQ ID NO: 1. The invention also provides a protein encoded by the Echinococcus granulosusglutathione transferase gene. The amino acid sequence of the protein encoded by the Echinococcus granulosusglutathione transferase gene is shown in SEQ ID NO: 2, or is the same as 1st-219th amino acid sequences as shown in SEQ ID NO: 3. The recombinant protein can be used for immunodiagnosis of cystic echinococcosis patients and can be used for coating a plate; and the serums of the patients having cystic echinococcosis, alveolitoid echinococcosis, cysticercosis and other parasite diseases and healthy people are detected by using an enzyme-linked immunosorbent assay (ELISA), and the obtained sensitivity and specificity are respectively 72.41% and 92.36%.

The invention relates to the field of zoonosis immune diagnosis and discloses a brucellosis antibody detection immunochromatography test strip based on colloidal gold as a marking material and a preparation method of the test strip. In a quick brucellosis antibody detection technology, the 40-nm colloidal gold labeled with staphylococcus aureus protein A (SPA) is sprayed on glass fibers to form a gold labeled pad. Genes OMP31 and BP26 are cloned from a brucella genome, form prokaryotic expression recombinant plasmids and are transformed in escherichia coli to express proteins omp31 and bp26, the two proteins as coating antigens are respectively coated on a nitrocellulose membrane to serve as detection lines, and the detection lines, the gold labeled pad, a specially treated sample loading pad and water absorption paper are assembled into an immunochromatography detection device. The test strip has the characteristics of strong specificity, high sensitivity, convenience, simplicity, economy and the like, can be applied to typing detection of brucellosis antibodies of sheep and cattle, and has very important meaning and practical application value for brucellosis monitoring and prevalence control.

The present invention relates to a solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent. The present invention also relates to a method for purifying a cysteine containing recombinantly expressed protein comprising at least 2, preferably 3 or 4 and even more preferably all of the following steps: (a) sulphonation of a lysate from recombinant host cells or lysis of recombinant host cells in the presence of guanidinium chloride followed by a subsequent sulphonation of the cell lysate, (b) treatment with a zwitterionic detergent, preferably after removal of the cell debris, (c) purification of the sulphonated version of the recombinant protein or purification of the sulphonated version of the recombinant protein with subsequent removal of the zwitterionic detergent, with said purification being preferably chromatography, more preferably a Ni-IMAC chromatography with said recombinant protein being a His-tagged recombinant protein, (d) desulphonation of the sulphonated version of the recombinant protein, preferably with a molar excess of DTT, (e) storage in the presence of a molar excess of DTT. The present invention also relates to novel HCV NS3 sequences as depicted in FIGS. 1-8.

The invention relates to a detection kit for hyperglycosylated modification of an hCG (human chorionic gonadotropin) tumor marker. According to the detection kit, magnetic beads are combined with an antibody (MCA-A) to serve as a capture antibody to capture total hCG in a to-be-detected sample, wherein the affinity of the antibody (MCA-A) is least influenced by glycosylation change; an antibody (MCA-B) most influenced by glycosylation change and another antibody (MCA-C) less influenced by glycosylation are used for detecting the total protein content and the N-glycosylation modification degree of hCG in the sample simultaneously, so that a tumor biomarker is identified. The detection kit improves the accuracy, the sensitivity and the specificity of an immunodiagnosis method greatly and has great practical value for detection of hyperglycosylated modification of the tumor marker in the actual sample.

The embodiment of the invention relates to the field of immunodiagnosis, in particular to a human alpha1-microglobulin (MG) determination kit with high sensitivity and a wide detection range. The human alpha1-MG determination kit provided by the embodiment of the invention comprises a reagent 1, a reagent 2 and human alpha1-MG calibration products of different gradient concentrations, wherein thereagent 2 comprises carboxylated latex microspheres labeled with a human alpha1-MG monoclonal antibody only and carboxylated latex microspheres labeled with a human alpha1-MG polyclonal antibody only;and the average particle size of the carboxylated latex microspheres labeled with the human alpha 1-MG monoclonal antibody only is larger than that of the carboxylated latex microspheres labeled withthe human alpha 1-MG polyclonal antibody. The human alpha1-MG determination kit provided by the invention can complete the detection of a single sample within 10 minutes with excellent precision, accuracy and anti-interference performance, can well reflect the renal tubular reabsorption function and glomerular filtration function, is very suitable for clinical biochemical analyzers, and greatly facilitates clinical examination.

The invention relates to a preparation method for a homogeneous enzyme immunodiagnosis reagent used for glycocholic acid, belonging to the technical field of biological medicine. The preparation method comprises the following steps: preparation of a glycocholic acid antibody solution; preparation of a glycocholic acid-enzyme conjugate solution; and preparation of a glycocholic acid calibrating substance. The glycocholic acid-enzyme conjugate solution is prepared by adding glycocholic acid into a MES buffer solution, adding a carboxyl activator for carboxyl activation, then adding 6-phosphogluconate dehydrogenase for a condensation reaction so as to obtain a crude glycocholic acid-enzyme conjugate product, carrying out dialysis and purification, adding the treated crude glycocholic acid-enzyme conjugate product into a Tris-HCl buffer solution, adding an auxiliary reagent and carrying out uniform mixing so as to obtain the glycocholic acid-enzyme conjugate solution. The homogeneous enzyme immunodiagnosis reagent for glycocholic acid prepared by using the method is safe, rapid, highly efficient and sensitive and can accurately detect the content of glycocholic acid in a to-be-detected sample.

The invention discloses a bovine Cryptosporidium ELISA detection kit. The kit comprises a coated ELISA plate, a negative standard serum, a positive standard serum, an enzyme-labeled second antibody, a washing liquid, a diluent, a substrate liquid and a stopping liquid, and the coated ELISA plate treats a concatermer COWP-HSP70 of COWP and a heat shock protein HSP70 as a coating antigen. The fusion interaction of the above two proteins is discussed through the series expression of the two proteins, and a coating antigen having a strong immunogenicity is obtained for the first time in the world because of the approximation to the self condition of the polypide. The kit and an ELISA method established in the invention are helpful for the deep development of the immunoprophylaxis and immunodiagnosis value researches of the bovine Cryptosporidium, and provide a necessary technical means for the fast detection and diagnosis of the bovine Cryptosporidium.

The invention discloses hepatitis C virus recombination protein, characterized in that: the hepatitis C virus recombination protein is fusion protein formed by fusing hepatitis C virus main antigenic determinant and hepatitis C virus core protein single chain antibody, and the amino acid sequence is represented as SEQ ID No.1. According to the invention, gene engineering recombination technology is utilized, the hepatitis C virus main antigenic determinant-core protein single chain antibody fusion protein is expressed in escherichia coli system, and the advantages of short production period, high yield and low cost are achieved. The recombination protein can be used as a part of an immunodiagnostic kit for hepatitis C virus.